康緣藥業(600557.SH):熱毒寧注射液列入《新型冠狀病毒肺炎診療方案(試行第九版)》
格隆匯3月17日丨康緣藥業(600557.SH)公佈,近日,國家衞生健康委員會辦公廳和國家中醫藥管理局辦公室聯合發佈《新型冠狀病毒肺炎診療方案(試行第九版)》,江蘇康緣藥業股份有限公司獨家品種熱毒寧注射液被該方案列為重型和危重型確診病例臨牀治療期推薦用藥;藿香正氣多劑型品種被該方案列為醫學觀察期推薦用藥。
熱毒寧注射液的功能主治:清熱、疏風、解毒。用於外感風熱所致感冒、咳嗽,症見高熱、微惡風寒、頭痛身痛、咳嗽、痰黃;上呼吸道感染、急性支氣管炎見上述證候者。
熱毒寧注射液系公司主營產品之一,2021年熱毒寧注射液銷售收入為46,959.03萬元,佔公司營業收入的比重為12.87%。此前,熱毒寧注射液已先後被納入《新型冠狀病毒肺炎診療方案》試行第六版、第七版和第八版,另外,熱毒寧注射液也先後被國家衞生和計劃生育委員會列為手足口病、H1N1、H7N9、登革熱等疫情診療方案的治療用藥。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.